Brief: Oncopeptides Extends Market Exclusivity For Pepaxti In Europe Until 2037
Feb 15 (Reuters) - Oncopeptides AB ONCO.ST :
* ENSURES FIVE YEARS EXTENDED MARKET EXCLUSIVITY FOR PEPAXTI
IN
EUROPE
* EXTENSION OF KEY PATENT IN EUROPE UNTIL 2037
Source text for Eikon: ID:nMFN9FCnfK
Further company coverage: ONCO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy